Pharmaceutical industry – Page 41
-
Business
Europe approves stem cell therapy
Treatment for burn-damaged eyes uses patient’s own scaffold-grown cells
-
Business
Valeant to buy Salix for $14.5bn
Companies expect $500m in savings through ‘R&D rationalisation’
-
OpinionTantalising technology
Computer-assisted drug design always looks like it’s just about to work, says Derek Lowe, but the reality is complicated
-
Business
Teva wins generic esomeprazole race
US approval of heartburn drug after Ranbaxy version was withdrawn by regulators
-
Business
US approves internal tissue glue
Urethane-based TissuGlu aids healing after abdominal surgery
-
Business
Hospira buyout is a shot in the arm for Pfizer’s biosimilars
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt
-
Business
EU regulator calls for generic drug suspensions
The EMA wants hundreds of formulations off the market after identifying systematic fraud in a major Indian contract clinical research organisation
-
BusinessRoche chases bolt-on acquisitions as it pushes into genomics
Company’s recent shopping spree aims to harness genome sequencing to advance personalised treatments
-
Business
Shire deepens rare disease focus with NPS buyout
Approval of parathyroid hormone drug further validates acquisition decision
-
Business
Ansun settles fraud case for $2m
Executives fiddled timesheets to overcharge US funding agency on grants and research contracts
-
Business
Biogen Idec to buy Convergence for pain pipeline
UK firm will remain intact as a ‘centre of excellence’ in pain R&D for Biogen
-
BusinessUS poised to approve its first ‘biosimilar’ drug
FDA panel recommends Sandoz’s copy of Amgen’s Neupogen
-
-
Business
EU recommends Parkinson’s drug for approval
First new molecule for a decade, but Alzheimer’s still posing challenges as antibody treatment withdrawn from trials
-
BusinessMerck & Co to buy antibiotics specialist Cubist
Pharma giant remains committed to $9.5bn deal despite key Cubist patents being invalidated by court ruling
-
BusinessSolving iron’s solubility problem
Technology profile: MRC Human Nutrition Research - anaemia supplements with fewer side effects
-
Business
Big pharma opens up abandoned drugs
Seven firms will make 68 stalled compounds available for academic research
-
Business
Otsuka to buy neurology specialist Avanir
$3.5bn deal adds to Otsuka’s mental health portfolio and strengthens its US presence
-
BusinessCystic Fibrosis Foundation sells drug royalty rights for $3.3bn
‘Venture philanthropy’ model pays off with massive cash injection for charity
-
OpinionProgress at the pace of the slowest
Chemistry is rarely the rate-limiting process in getting a drug to market, says Derek Lowe